GuideNeurology
PML risk with natalizumab in multiple sclerosis
Factors that stratify the risk of progressive multifocal leukoencephalopathy (PML) in MS patients treated with natalizumab.
Updated 3 November 2026
When to use it
Before starting natalizumab and at each benefit-risk reassessment (at least yearly).
Warning
The original tool's risk table is outdated. Figures here are indicative; use the current product information for individual decisions.
What it is
PML is an opportunistic CNS infection by JC virus that can occur with natalizumab. Risk is not uniform: it is stratified with simple data available in clinic. Published risk tables come from the manufacturer and observational cohorts and have been updated over time.
Keep reading in the app
- Risk factors
- Published figures (Ho 2017)
- How it is used in practice
- Limitations
Practical tip
The three classic factors are: positive anti-JCV antibodies, prior immunosuppressants and treatment duration (especially beyond 24 months).
3 more practical tips in the app.
Reference
- Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
- Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925-933.
- Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76(6):802-812.
- Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452-e1462.
Official source: Tysabri: official EMA information
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
